$7.68

0.48 (6.67%)

11/21/2008 4:00 PM

Progenics Pharmaceuticals, Inc. (PGNX)

CAPS Rating:

A biopharmaceutical company focusing on the development and commercialization of innovative therapeutic products to treat the unmet medical needs of patients with debilitating conditions and life-threatening diseases.

Rating a stock in CAPS consists of three components:

Your call - Will this stock outperform or underperform the S&P 500? Successful picks are measured in terms of whether or not you were correct and by how many percentage points.

Your time frame - A guideline for other members to see whether your thinking is short or long-term. Time frame is also used to calculate the stock rating, but is not used in the scoring of your pick.

Your pitch - Here's your chance to offer more detailed thoughts, analysis, concerns, or the rationale behind your call. The pitch is optional and may be added later.

Each time you rate a stock, CAPS updates the community intelligence for the company, which may or may not change its CAPS rating. For more information, visit the Help tab at the top of the page.

You aren't currently rating PGNX

Add Stock to Watchlist

What the Community Thinks

Total Members

119 Outperforms

11 Underperforms

All-Stars

18 Outperforms

7 Underperforms

Wall Street

10 Outperforms

0 Underperforms

Members bullish on PGNX are also bullish on:

Members bearish on PGNX are also bearish on:

Ticker Tags

Micro Cap (5043), Biotechnology (230), Drug Manufacturers - Other (7)
Suggest a tag

Progenics Pharmaceuticals, Inc. At A Glance

Current Price:	$7.68
Last Trade Time:	11/21/2008 4:00 PM
Open:	$7.34
Previous Close:	$7.20
Daily Range:	$6.77 - $7.79
52-Week Range:	$4.33 - $22.38
Volume:	464,619
Market Cap:	$219.28M
P/E Ratio:	0.00
Compare Our Special Broker Offers!

Stock Trends

PGNX VS S&P 500 (SPY)

News & Discussion Boards

Other News Headlines for PGNX

Wyeth, Progenics get European constipation drug OK
7/3/2008 1:23:00 PM - AP
Progenics rises on oral Relistor mid-stage trial data
5/22/2008 6:53:00 PM - AP
Wyeth, Progenics drug misses goal in late-stage trial
5/22/2008 9:40:00 AM - AP
Earnings roundup: Delphi, Iomega
5/9/2008 6:31:00 PM - AP

More Headlines...

Top Bull Pitch

Recs

1 Progenics Pharmaceuticals, Inc. (PGNX)

Avatar 1760mill (64.34) Submitted: 9/15/06 2:56 AM

Drug for opioid-induced constipation has had very good trial results. FDA submission next year. Also discovered receptor HIV uses to enter cells, a potential blockbuster drug target, but still pretty far off.

Replies: 0 | Reply | Permalink

Top Bear Pitch

There are no pitches that meet the Top Bear criteria. Explain

If this upsets you, start recommending pitches below!

CAPS Members

Show Me:

Sort by:

picks per page. CHANGE

Results 1 - 5 of 18 : 1 2 3 4 Next »

Show Pitch Replies

Recs 0 (PGNX) zzlangerhans (99.48) Submitted: 10/12/08 1:15 PM : Start Price: $11.00 PGNX Score: -16.95 Your leader returns to his adoring subjects. Subcu MNTX is approved and has clocked some initial sales, which are at a level I would describe as encouraging. While Progenics won't become profitable based on this, it gives them some cushion as they develop the oral form of the drug and work on their other longshot projects, such as Pro140 for HIV. In the meantime having a marketed compound makes them a potential buyout candidate for Wyeth. I'm looking for a rebound to the 15 range as the market sphincter relaxes. Report this Post Replies: 2 \| Reply \| Permalink Oops! There appears to be a problem with your comment. Check to see if there's something you left out. Recs 0 (PGNX) OOooMercuryooOO (< 20) Submitted: 8/15/08 7:10 PM : Start Price: $13.37 PGNX Score: -0.70 Down on no news - owned this through FDA and EMEA approvals but then sold out - back now since it's at the same levels again but closer to profitability and/or buyout (Wyeth?) Report this Post Replies: 0 \| Reply \| Permalink Oops! There appears to be a problem with your comment. Check to see if there's something you left out. Recs 0 (PGNX) Vinman2 (< 20) Submitted: 6/17/08 11:57 PM : Start Price: $16.85 PGNX Score: -10.79 Sales of Relistor are just starting in the US for terminal patients with advanced medical illness. Their partner Wyeth has a large sales force ramped up and ready to go. Sales will likely be far greater than intitial estimates due to a higher price and significant off label usage. Approval will be granted in Europe and Australia later this year. PGNX could still earn about $300 million in milestone payments from Wyeth from Relistor, assuiomg it getst approved for chroinic pain. Their anti-HIV antibody, which blocks HIV entiry via the CCR5 receptor, should generate excellent results in two phase II trials. These trials are in progress and will be completed by year's end or early 2009. PRO140 is still fully owned by PGNX so partnership dollars could roll in next year. Report this Post Replies: 0 \| Reply \| Permalink Oops! There appears to be a problem with your comment. Check to see if there's something you left out. Recs 0 (PGNX) timmymac61 (27.65) Submitted: 6/05/08 8:27 AM : Start Price: $16.30 PGNX Score: -7.53 has found a firm base will retest mid to high twentys by end of fall Report this Post Replies: 2 \| Reply \| Permalink Oops! There appears to be a problem with your comment. Check to see if there's something you left out. Recs 0 (PGNX) MisterGee453 (31.32) Submitted: 5/01/08 12:39 PM : Start Price: $10.85 PGNX Score: 16.43 With people living longer and longer, new technologies are needed to assure quality products are in place to facilitate that trend. Report this Post Replies: 0 \| Reply \| Permalink Oops! There appears to be a problem with your comment. Check to see if there's something you left out.
Results 1 - 5 of 18 : 1 2 3 4 Next »

Wall Street

Results 1 - 10 of 10

picks per page. CHANGE

Top Pick	Member Name	Member Rating	Start Date	Call	Time Frame	Start Price	Stock Gain	S&P Gain	Score	Pitch
	TrackLadenburg	50.70	05/12/08		NS	$12.33	-37.71%	-45.96%	+8.25
	TrackBreanMurray	61.07	03/12/08		NS	$5.04	+52.38%	-42.71%	+95.10
	TrackBroadpointC	< 20	11/08/07		NS	$21.56	-64.38%	-48.32%	-16.06
	TrackBofASec	95.85	09/26/07		NS	$22.91	-66.48%	-50.19%	-16.29
	TrackPZK	< 20	03/07/07		NS	$23.18	-66.87%	-45.81%	-21.06
	TrackRBCCapMkts	33.03	01/29/07		NS	$30.02	-74.42%	-46.67%	-27.75
	TrackFirstAlbany	27.62	12/22/06		NS	$26.12	-70.60%	-46.46%	-24.14
	TrackAmTechJSA	53.72	11/06/06		NS	$26.00	-70.46%	-44.63%	-25.83
	TrackPiperJaff	< 20	08/22/06		NS	$21.33	-63.99%	-41.66%	-22.33
	TrackJimCramer	85.65	04/26/06		3W	$22.59	-66.00%	-42.05%	-23.95

Results 1 - 10 of 10

Beat this Stock

Clicking "Beat this Stock!" will bring you to a company with a higher rating than the one you're currently viewing.

Even though CAPS shows only one- to five-star rankings, behind the scenes, all companies in CAPS have a distinct numerical ranking. In other words, there is a No. 1 stock in CAPS and a worst-ranked stock in CAPS. When you arrive at the top-ranked stock, clicking "Beat this Stock!" will cause the page to refresh.

That is, until there is a new No. 1 stock!

These companies do not represent formal Motley Fool recommendations. Please do your own due diligence before investing. Fool on.